Mirion Technologies Announces Pricing of Upsized Public Offering

09/26/2025 – 12:01 AM

ATLANTA – Mirion Technologies, Inc. (NYSE: MIR), a key player in radiation safety, science, and medicine, announced the pricing of its upsized underwritten public offering, signaling a robust strategy for growth and market expansion. The company will offer 17,309,846 shares of its Class A common stock at a price of $21.35 per share, increasing the offering from the previously announced $350 million target. This move underscores investor confidence in Mirion’s trajectory and strategic direction.

Moreover, underwriters have been granted an option to purchase an additional 2,596,476 shares of Class A common stock at the offering price, net of underwriting discounts and commissions. The common stock offering is anticipated to close on September 30, 2025, contingent upon customary closing conditions.

Leading financial institutions, including Goldman Sachs & Co. LLC, Evercore ISI, Citigroup, Morgan Stanley, Baird, and Truist Securities, are serving as joint book-running managers for the offering. CJS Securities and B. Riley Securities are acting as co-managers.

Mirion anticipates net proceeds of approximately $356.2 million from the common stock offering, after accounting for underwriting discounts, commissions, and offering expenses. The company intends to allocate these funds strategically, primarily towards (i) covering the costs associated with capped call transactions related to its concurrent convertible notes offering and (ii) financing its planned acquisition of Paragon Energy Solutions, LLC, a move poised to strengthen Mirion’s market position in the energy sector. In the event the acquisition does not materialize, remaining funds will be used for general corporate purposes.

Concurrently, Mirion announced the pricing of a $325.0 million offering of Convertible Senior Notes due 2031 to qualified institutional buyers under Rule 144A of the Securities Act of 1933. The size of this offering was also increased from the initially announced $250.0 million. Furthermore, initial purchasers have an option to acquire an additional $50.0 million aggregate principal amount of notes within a 13-day period following the initial issuance. The convertible notes offering is also expected to close on September 30, 2025, pending standard closing conditions. The closing of either offering is not contingent on the other, providing Mirion with financial flexibility.

The common stock offering is being conducted under a shelf registration statement filed with the Securities and Exchange Commission (SEC). Potential investors are encouraged to review the prospectus supplement and accompanying prospectus, along with other relevant SEC filings, for comprehensive information about Mirion and the offering. These documents are accessible on the SEC’s EDGAR database.

This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities, nor will any sale occur in jurisdictions where such activities are unlawful prior to registration or qualification under securities laws.

Mirion’s strategic moves come at a time when the demand for radiation safety technologies is increasing, driven by growing nuclear power generation, advancements in medical imaging, and rising concerns over industrial safety. The acquisition of Paragon Energy Solutions, in particular, is expected to significantly enhance Mirion’s presence in the nuclear energy sector, providing access to critical engineering services and specialized equipment for nuclear power plants. The company’s focus on enhancing patient outcomes through medical solutions also presents significant growth opportunities, as the demand for quality cancer care continues to rise globally.

The dual financing strategy – common stock offering and convertible notes – allows Mirion to raise capital efficiently while maintaining a balanced capital structure. The capped call transactions associated with the convertible notes are designed to mitigate potential dilution from the conversion of the notes, further optimizing shareholder value.

Forward-Looking Statements

This release contains forward-looking statements regarding the timing and completion of the offerings and the anticipated use of proceeds. These statements are subject to risks and uncertainties, including market risks, trends, and conditions. Actual results may differ materially. Investors should review Mirion’s filings with the SEC for a comprehensive risk assessment.

About Mirion

Mirion (NYSE: MIR) is a global leader in radiation safety, science, and medicine. The company empowers innovations delivering vital protection and harnessing the transformative potential of ionizing radiation. Mirion Technologies focuses on nuclear safety and power advancements, while Mirion Medical is dedicated to improving cancer care outcomes. Headquartered in Atlanta, USA, Mirion operates in 12 countries with approximately 2,800 employees.